SCM
MPLT

Superstring Capital Management’s MapLight Therapeutics MPLT Stock Holding History

Superstring Capital Management’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.5M Sell
125,432
-66,707
-35% -$1.92M 2.84% 14
2026
Q1 		$3.91M Buy
+192,139
New +$3.44M 2.79% 15

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Superstring Capital Management's MPLT Position: Q2 2026 in Review

Superstring Capital Management reduced its MapLight Therapeutics (MPLT) stake by 35% in Q2 2026, selling an estimated $1.92M and leaving 125,432 shares worth $4.5M. The position accounts for 2.84% of the portfolio, ranked #14.

Superstring Capital Management first reported a position in MPLT in Q1 2026 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Superstring Capital Management held 125,432 shares of MapLight Therapeutics worth $4.5M as of Q2 2026.
  • Superstring Capital Management sold 66,707 MapLight Therapeutics shares in Q2 2026, an estimated $1.92M.
  • MapLight Therapeutics made up 2.84% of Superstring Capital Management's portfolio in Q2 2026, its #14 holding.
  • Superstring Capital Management first reported a position in MapLight Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.